FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer

被引：0
|
作者：
Shao Zhimin
Fan, Lei
Ma Linxiaoxi
Wu, Songyang
Chen, Li
Liu, Xiyu
Zhang, Wenjuan
Hu, Xin
Jiang, Yizhou
Wang, Zhonghua
Li, Huajun
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Med Coll, Dept Oncol, Key Lab Breast Canc Shanghai, Shanghai, Peoples R China
[4] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3011
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II trial of biweekly vinorelbine and oxaliplatin in second-or third-line metastatic triple-negative breast cancer
    Zhang, Jian
    Wang, Leiping
    Wang, Zhonghua
    Hu, Xichun
    Wang, Biyun
    Cao, Jun
    Lv, Fangfang
    Zhen, Chunlei
    Zhang, Sheng
    Shao, Zhimin
    CANCER BIOLOGY & THERAPY, 2015, 16 (02) : 225 - 232
  • [42] First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
    Schmid, Peter
    Turner, Nicholas C.
    Barrios, Carlos H.
    Isakoff, Steven J.
    Kim, Sung-Bae
    Sablin, Marie-Paule
    Saji, Shigehira
    Savas, Peter
    Vidal, Gregory A.
    Oliveira, Mafalda
    O'Shaughnessy, Joyce
    Italiano, Antoine
    Espinosa, Enrique
    Boni, Valentina
    White, Shane
    Rojas, Beatriz
    Freitas-Junior, Ruffo
    Chae, Yeesoo
    Bondarenko, Igor
    Lee, Jieun
    Mattos, Cesar Torres
    Rodriguez, Jorge Luis Martinez
    Lam, Lisa H.
    Jones, Surai
    Reilly, Sarah-Jayne
    Huang, Xiayu
    Shah, Kalpit
    Dent, Rebecca
    CLINICAL CANCER RESEARCH, 2024, 30 (04) : 767 - 778
  • [43] Phase II trial of selinexor for metastatic triple negative breast cancer
    Han, H. S.
    Ismail-Khan, R.
    Carney, D.
    Extermann, M.
    Hogue, D.
    Soliman, H.
    Loftus, L.
    Lee, J. K.
    Sullivan, D.
    CANCER RESEARCH, 2017, 77
  • [44] Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): Subgroup analysis of TURANDOT
    Inbar, Moshe J.
    Lang, Istvan
    Kahan, Zsuzsanna
    Greil, Richard
    Beslija, Semir
    Stemmer, Salomon M.
    Kaufman, Bella
    Ahlers, Silke
    Brodowicz, Thomas
    Zielinski, Christoph
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer
    Brufsky, Adam
    Hoelzer, Karen
    Beck, Thaddeus
    Whorf, Robert
    Keaton, Mark
    Nadella, Padma
    Krill-Jackson, Elisa
    Kroener, Joan
    Middleman, Edward
    Frontiera, Michael
    Paul, Devchand
    Panella, Timothy
    Bromund, Jane
    Zhao, Luping
    Orlando, Mauro
    Tai, Fritz
    Marciniak, Martin D.
    Obasaju, Coleman
    Hainsworth, John
    CLINICAL BREAST CANCER, 2011, 11 (04) : 211 - 220
  • [46] A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer
    Joanne L. Blum
    Anthony Gonçalves
    Noa Efrat
    Marc Debled
    Pierfranco Conte
    Paul D. Richards
    Donald Richards
    Pilar Lardelli
    Antonio Nieto
    Martin Cullell-Young
    Suzette Delaloge
    Breast Cancer Research and Treatment, 2016, 155 : 295 - 302
  • [47] A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer
    Blum, Joanne L.
    Goncalves, Anthony
    Efrat, Noa
    Debled, Marc
    Conte, Pierfranco
    Richards, Paul D.
    Richards, Donald
    Lardelli, Pilar
    Nieto, Antonio
    Cullell-Young, Martin
    Delaloge, Suzette
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (02) : 295 - 302
  • [48] Phase II trial of RAMO I plus carhoplatin in patients with triple-negative metastatic breast cancer
    Singh, J. C.
    Stein, S.
    Volm, M.
    Smith, J. A.
    Novik, Y.
    Speyer, J. L.
    Adams, S.
    Meyers, M. I.
    Muggia, F.
    Schneider, R.
    Formenti, S.
    Davis, S.
    Choi, H.
    Tiersten, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [49] A Phase II study of cabozantinib for metastatic triple-negative breast cancer (TNBC).
    Tolaney, Sara M.
    Ziehr, David R.
    Guo, Hao
    Barry, William Thomas
    Higgins, Michaela Jane
    Isakoff, Steven J.
    Brock, Jane E.
    Ivanova, Elena
    Paweletz, Cloud
    Demeo, Michelle
    Ramaiya, Nikhil H.
    Overmoyer, Beth
    Jain, Rakesh K.
    Duda, Dan G.
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] Activity and safety of vinorelbine and capecitabine as first-line treatment in patients with metastatic breast cancer - a phase II trial
    Palumbo, R.
    Bernardo, A.
    Strada, M.
    Teragni, C.
    Poggi, G.
    Frascaroli, M.
    Amatu, A.
    Palumbo, I.
    Bernardo, G.
    EJC SUPPLEMENTS, 2008, 6 (07): : 177 - 177
12345